Browsing Tag
REGENETEN
2 posts
SN share price firms as Smith+Nephew launches $500m buyback and Cevian Capital adds to 5% activist stake
Cevian wants a breakup. Deepak Nath wants RISE to deliver. The $500m buyback is the bridge. H2 2026 is where the real test of the Smith+Nephew thesis lands.
Smith+Nephew Q3 2025: Can the CATALYSTEM rollout and REGENETEN momentum offset VBP risks?
Smith+Nephew raises 2025 free cash flow guidance to USD 750 million as margin growth accelerates. Find out what’s driving the company’s transformation.